Hexin (Suzhou) Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 6

Hexin (Suzhou) General Information

Description

Developer of nuclide drugs designed to integrate targeted diagnosis and treatment. The company's drugs utilize the core technology of positron emission tomography (PET) contrast agents and targeted radiotherapy, enabling healthcare providers to diagnose and treat pancreatic cancers more effectively.

Contact Information

Website
hexin-med.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Building 5, No. 90, Zhaoxi Road
  • Shaxi Town, Taicang
  • Suzhou, Jiangsu 215421
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4th Floor, Building 5, No. 90, Zhaoxi Road
  • Shaxi Town, Taicang
  • Suzhou, Jiangsu 215421
  • China
+86 0512

Hexin (Suzhou) Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hexin (Suzhou) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 08-May-2025 Completed Clinical Trials - Phase 1
3. Early Stage VC 30-Jan-2024 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 03-Mar-2023 $14.6M $14.6M Completed Clinical Trials - Phase 1
1. Seed Round 08-Feb-2021 Completed Startup
To view Hexin (Suzhou)’s complete valuation and funding history, request access »

Hexin (Suzhou) Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • Pending

  • Expiring in next 12 mo

Hexin (Suzhou) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024114792-A1 Heterodimer and radioactive medical use thereof Inactive 01-Dec-2022
JP-2025538623-A Heterodimers and their radioactive medical applications Active 01-Dec-2022
WO-2024046469-A1 Cyclic peptide and preparation method therefor, and complex comprising same and use thereof Inactive 02-Sep-2022
JP-2025529255-A Cyclic peptides, methods for preparing same, complexes containing same and uses thereof Active 02-Sep-2022 C07K7/64

Hexin (Suzhou) Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
China National Nuclear Government Minority
CAS Star Venture Capital Minority
Cowin Capital Venture Capital Minority
Sunland Fund Venture Capital Minority
Xiangtang Ventures Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Hexin (Suzhou) FAQs

  • When was Hexin (Suzhou) founded?

    Hexin (Suzhou) was founded in 2020.

  • Where is Hexin (Suzhou) headquartered?

    Hexin (Suzhou) is headquartered in Suzhou, China.

  • What industry is Hexin (Suzhou) in?

    Hexin (Suzhou)’s primary industry is Drug Discovery.

  • Is Hexin (Suzhou) a private or public company?

    Hexin (Suzhou) is a Private company.

  • What is Hexin (Suzhou)’s current revenue?

    The current revenue for Hexin (Suzhou) is .

  • How much funding has Hexin (Suzhou) raised over time?

    Hexin (Suzhou) has raised $14.6M.

  • Who are Hexin (Suzhou)’s investors?

    China National Nuclear, CAS Star, Cowin Capital, Sunland Fund, and Xiangtang Ventures are 5 of 6 investors who have invested in Hexin (Suzhou).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process